Annex C Biokinetic models and dose tables

Atkins H.L. Christman D.R. Fowler J.S. , 1972. Organic Radiopharmaceuticals Labeled with Isotopes of Short Half-Life. V. 18F-Labeled 5- and 6-Fluorotryptophan. J. Nucl. Med. 13, 713–719.

Bergmann R. Brust P. Kampf G. Coenen H.H. Stöcklin G. , 1995. Evaluation of radioselenium labeled selenomethionine, a potential tracer for brain protein synthesis by PET. Nucl. Med. Biol. 22, 475–481.

Coenen H.H. Kling P. Stöcklin G. , 1989. Cerebral metabolism of 1-[2-¹⁸F]fluorotyrosine, a new PET tracer of protein synthesis. J. Nucl. Med. 30, 1367–1372.

Cottrall M.F. Taylor D.M. McElwain T.J. , 1973. Investigations of ¹⁸F-p-fluorophenylalanine for pancreas scanning. Br. J. Radiol. 46, 277–288.

Deloar H.M. Fujiwara T. Nakamura T. Itoh M. Imai D. Miyake M. Watanuki S. , 1998b. Estimation of internal absorbed dose of 1-[methyl-¹¹C] methionine using whole body positron emission tomography. Eur. J. Nucl. Med. 25, 629–633.

ICRP, 1987. Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53. Ann. ICRP 18, 149–150.

Inoue T. Tomiyoshi K. Higuichi T. Ahmed K. Sarwar M. Aoyagi K. Amano S. Alyafei S. Zhang H. Endo K. , 1996. Biodistribution studies on 1–3-[fluorine-18]fluoro-α-methyl tyrosine: Potential tumor-detecting agent. J. Nucl. Med. 39, 663–667.

Schmidt D. Langen K-J. Herzog H. Wirths J. Holschbach M. Kiwit J.C.W. Ziemons K. Coenen H.H. Müller-Gärtner H.W. , 1997. Whole-body kinetics and dosimetry of 1–3-[¹²³I]iodo-α-methyltyrosine. Eur. J. Nucl. Med. 24, 1162–1166.

Shoup T.M. Olson J. Hoffman J.M. Votaw J. Eshima D. Eshima L. Camp M. Stabin M. Votaw D. Goodman M. , 1999. Synthesis and evaluation of [¹⁸F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumours. J. Nucl. Med. 40, 331–338.

Stenhouse M.J. Baxter M.S. , 1977. Bomb ¹⁴C as a biological tracer. Nature (Lond.) 267, 828–832.

Stenström K. Leide-Svegborn S. Erlandsson B. Hellborg R. Mattsson S. Nilsson L-E. Nosslin B. Skog G. Wiebert A. , 1996. Application of accelerator mass spectrometry (AMS) for high-sensitivity measurements of ¹⁴CO₂ in long-term studies of fat metabolism. Appl. Radiat. Isot. 47, 417–422.

Taylor D.M. , 2000b. Generic models for radionuclide dosimetry: ¹¹C, ¹⁸F or ⁷⁵Se-labelled amino acids. Appl. Radiat. Isot. 52, 911–922.

Taylor D.M. Cottrall M.F. , 1973. Evaluation of amino acids labelled with ¹⁸F for pancreas scanningRadiopharmaceuticals and Labelled Compounds, Vol. I. IAEA, Vienna, pp. 441–443.

Wester H.J. Herz M. Senkowitsch-Schmidtke R. Schwaiger M. Stöcklin G. Hamacher K. , 1999a. Preclinical evaluation of 4-[¹⁸F]fluoroprolines: diasteromeric effect on metabolism and uptake in mice. Nucl. Med. Biol. 26, 259–265.

Wester H.J. Herz M. Weber W. Heiss P. Senkowitsch-Schmidtke R. Schwaiger M. Stöcklin G. , 1999b. Synthesis and radiopharmacology of O-(2-[¹⁸F]fluoroethyl)-1-tyrosine for tumor imaging. J. Nucl. Med. 40, 205–212.

Burns H.D. Dannals R.F. Langström B. Ravert H.T. Zemyan S.E. Duelfer T. Wong D.F. Frost J.J. Kuhar M.J. Wagner H.N. , 1984. 3-N-[¹¹C]methylspiperone, a ligand binding to dopamine receptors: radiochemical synthesis and biodistribution studies in mice. J. Nucl. Med. 25, 1222–1227.

Farde L. Hall H. Ehrin E. Sedvall G. , 1986. Quantitative analysis of D2 dopamine receptor binding in the living human brain. Science 231, 258–261.

Farde L. Suhara T. Nyberg S. Karlsson P. Nakashima Y. Hietala J. Halldin C. , 1997. A PET study of [¹¹C]FLB 457 binding to extrastriatal D₂-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology 133, 394–404.

Frost J.J. Mayberg H.S. Sadzot B. Dannals R.F. Lever J.R. Ravert H.T. Wilson A.A. Wagner H.N. Jr. Links J.M. , 1990. Comparison of [¹¹C]diprenorphine and [¹¹C]carfentanil binding to opiate receptors in humans by positron emission tomography. J. Cereb. Blood Flow Metab. 10, 484–492.

Herscovitch P. Schmall B. Doudet D. Carson R. Eckelman W. , 1997. Biodistribution and radiation dose estimates for [¹¹-C]raclopride (abstract). J. Nucl. Med. 5 (Suppl.), 224.

Houle S. DaSilva J.N. Wilson A.A. , 2000a. Imaging the 5-HT_1A receptors with PET: WAY-100635 and analogues. Nucl. Med. Biol. 27, 463–466.

Houle S. Ginovart N. Hussey D. Meyer J.H. Wilson A.A. , 2000b. Imaging the serotonin transporter system with positron emission tomography: Initial human studies with [¹¹C]DAPP and [¹¹C]DASB. Eur. J. Nucl. Med. 27, 1719–1722.

ICRP, 1987. Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53. Ann. ICRP 18 (1–4).

Iyo M. Namba H. Fukushi K. Shinotoh H. Nagatsuka S. Suhara T. Sudo Y. Suzuki K. Irie T. , 1997. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 349, 1805–1809.

Kim S. Wagner H.N. Jr. Villemagne V.L. Kao P-F. Dannals R.F. Ravert H.T. Joh T. Dixon R.B. Civelik A.C. , 1997. Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual detector system. J. Nucl. Med. 38, 1726–1731.

McClain D.A. Hug C.C. Jr. , 1980. Intravenous fentanyl kinetics. Clin. Pharmacol. Ther. 28, 106–114.

Mulholland G.K. Kilbourn M.R. Sherman P. Carey J.E. Frey K.A. Koeppe R.A. Kuhl D.E. , 1995. Synthesis, in vivo biodistribution and dosimetry of [¹¹C]N-methylpiperidyl benzilate ([¹¹C]NMPB), a muscarinic acetylcholine receptor antagonist. Nucl. Med. Biol. 22, 13–17.

Nosslin B. Johansson L. Leide-Svegborn S. Liniecki J. Mattsson S. Taylor D. , 2003. A generic model for 11C-labelled radiopharmaceuticals for imaging receptors in the human brain, Presented at Workshop of Internal Dosimetry of Radionuclides in Oxford, 9–12 September 2002. Rad. Prot. Dosim. 105, 587–591.

Olsson H. Halldin C. Swahn G. Farde L. , 1999. Quantification of [¹¹C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. J. Cereb. Blood Flow Metab. 19, 1164–1173.

Osman S. Lundkvist C. Pike V.W. Halldin C. McCarron J.A. Swahn C-G. Ginovart N. Luthra S.K. Bench C.J. Grasby P.M. Wikström H. Barf T. Cliffe I.A. Fletcher A. Farde L. , 1996. Characterization of the radioactive metabolites of the 5-HT_1A receptor radioligand, [O-methy-¹¹C]-WAY-100635, in monkey and human plasma by HPLC: comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET. Nucl. Med. Biol. 23, 627–634.

Pappata S. Samson Y. Chavoix C. Prenant C. Mazière M. Baron J.C. , 1988. Regional specific binding of [¹¹C]RO 15 1788 to central type benzodiazepine receptors in human brain: quantitative evaluation by PET. J. Cereb. Blood Flow Metab. 8, 304–313.

Persson A. Pauli S. Swahn C.G. Halldin C. Sedvall G. , 1989. Cerebral uptake of ¹¹C-Ro 15 1788 and its acid metabolite ¹¹C-Ro 15 3890: PET study in human volunteers. Human Psychopharmacol. 4, 215–220.

Pike V.W. McCarron J.A. Hume S.P. Ashworth S. Opacka-Juffry J. Osman S. Lammertsma A.A. Poole K.G. Fletcher A. White A.C. Cliffe I.A. , 1995. Preclinical development of a radioligand for studies of central 5-HT1A receptors in vivo — [¹¹C]WAY-100635. Med. Chem. Res. 5, 208–227.

Szabo Z. Scheffel U. Mathews W.B. Ravert H.T. Szabo K. Kraut M. Palmon S. Ricaurte G.A. Dannals R.F. , 1999. Kinetic analysis of [¹¹C]McN5652: a serotonin transporter radioligand. J. Cereb. Blood Flow Metab. 19, 967–981.

Tanaka N. Fukushi K. Shinotoh H. Nagatsuka S. Namba H. Iyo M. Aotsuka A. Ota T. Tanada S. Irie T. , 2001. Positron emission tomographic measurement of brain acetylcholinesterase activity using N-[¹¹C]methylpiperidin-4-yl acetate without arterial blood sampling: methodology of shape analysis and its diagnostic power for Alzheimer's disease. J. Cereb. Blood Flow Metab. 21, 295–306.

Verhoeff N.P. Buseman Sokole E.B. Hengst D. Stubbs J.B. van Royen E.A. , 1993. Dosimetry of iodine-123 iomazenil in humans. Eur. J. Nucl. Med. 20, 580–584.

Volkow N.D. Ding Y.-S. Fowler J.S. Wang G.-J. Logan J. Gatley S.J. Schlyer D.J. Pappas N. , 1995. A new PET ligand for the dopamine transporter: Studies in human brain. J. Nucl. Med. 36, 2162–2168.

Votaw J.R. Ansari M.S. Scott Mason N. Schmidt D. de Paulis T. Holburn G. Clanton J.A. Votlaw D.B. Manning R.G. Kessler R.M. , 1995. Dosimetry of iodine-123-epidepride: A dopamine D2 receptor ligand. J. Nucl. Med. 36, 1316–1321.

Westera G. Buck A. Burger C. Leenders K.L. von Schultness G.K. Schubiger A.P. , 1996. Carbon-11 and iodine-123 labelled iomazenil: A direct PET-SPECT comparison. Eur. J. Nucl. Med. 23, 5–12.

Wilson A.A. Inaba T. Fischer N. Dixon L.M. Nobrega J. DaSilva J.N. Houle S. , 1998. Derivatives of WAY 100635 as potential imaging agents for 5-HT1A receptors: Syntheses, radiosyntheses, and in vitro and in vivo evaluation. Nucl. Med. Biol. 25, 769–776.

Comar D. Catron J.C. Maziere M. Marazanop C. , 1976. Labelling and metabolism of methionine-methyl-¹¹C. Eur. J. Nucl. Med. 1, 11–14.

Deloar H.M. Fujiwara T. Nakamura T. Itoh M. Imai D. Miyake M. Watanuki S. , 1998b. Estimation of internal absorbed dose of L-[methyl-¹¹C]-methionine using whole body positron emission tomography. Eur. J Nucl. Med. 25, 629–633.

Berridge M.S. Adler L.P. Rao P.S. , 1991. Radiation absorbed dose for O-15-butanol and O-15 water estimated by positron emission tomography. J. Nucl. Med. 32, 1043.

Brihaye C. Depresseux J.C. Comar D. , 1995. Radiation dosimetry for bolus administration of oxygen-15 water. J. Nucl. Med. 36, 651–656.

Eichling J.O. Bergman S.R. Schwarz S.W. Siegel B.A. 1997. Equivalent dose estimates in adults for intravenously administered O-15 water. Unpublished; personal communication through S. Schwarz.

Herscovitch P. Carson R.E. Stabin M. , 1993. A new kinetic approach to estimate the radiation dosimetry of flow-based radiotracers. J. Nucl. Med. 34, 155P.

Coenen H.H. Kling P. Stöcklin G. , 1989. Cerebral metabolism of 1-[2-¹⁸F]Fluorotyrosine, a new PET tracer of protein synthesis. J. Nucl. Med. 30, 1367–1372.

Cottrall M.F. Taylor D.M. McElwain T.J. , 1973. Investigations of ¹⁸F-p-fluorophenylalanine for pancreas scanning. Br. J. Radiol. 46, 277–288.

ICRP, 1987. Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53. Ann. ICRP 18 (1–4), 149–150.

ICRP, 2001b. Radiation dose to patients from radiopharmaceuticals. Addendum 4 to ICRP Publication, 53.

Inoue T. Tomiyoshi K. Higuichi T. Ahmed K. Sarwar M. Aoyagi K. Amano S. Alyafei S. Zhang H. Endo K. , 1996. Biodistribution studies on 1–3-[Fluorine-18]fluoro-α-methyl tyrosine: A potential tumor-detecting agent. J. Nucl. Med. 39, 663–667.

Schmidt D. Langen K-J. Herzog H. Wirths J. Holschbach M. Kiwit J.C.W. Ziemons K. Coenen H.H. Müller-Gärtner H.W. , 1997. Whole-body kinetics and dosimetry of 1–3-[¹²³I]iodo-α-methyltyrosine. Eur. J. Nucl. Med. 24, 1162–1166.

Shoup T.M. Olson J. Hoffman J.M. Votaw J. Eshima D. Eshima L. Camp M. Stabin M. Votaw D. Goodman M. , 1999. Synthesis and evaluation of [¹⁸F]1-Amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumours. J. Nucl. Med. 40, 331–338.

Stenhouse M.J. Baxter M.S. , 1977. Bomb ¹⁴C as a biological tracer. Nature (Lond.) 267, 828–832.

Stenström K. Leide-Svegborn S. Erlandsson B. Hellborg R. Mattsson S. Nilsson L-E. Nosslin B. Skog G. Wiebert A. , 1996. Application of accelerator mass spectrometry (AMS) for high-sensitivity measurements of ¹⁴CO₂ in long-term studies of fat metabolism. Appl. Radiat. Isot. 47, 417–422.

Taylor D.M. , 2000b. Generic models for radionuclide dosimetry: ¹¹C, ¹⁸F or ⁷⁵Se-labelled amino acids. Appl. Radiat. Isot. 52, 911–922.

Taylor D.M. Cottrall M.F. , 1973. Evaluation of amino acids labelled with ¹⁸F for pancreas scanningRadiopharmaceuticals and Labelled Compounds, Vol. I. IAEA, Vienna, pp. 441–443.

Wester H.J. Herz M. Senkowitsch-Schmidtke R. Schwaiger M. Stöcklin G. Hamacher K. , 1999a. Preclinical evaluation of 4-[¹⁸F]fluoroprolines: diasteromeric effect on metabolism and uptake in mice. Nucl. Med. Biol. 26, 259–265.

Wester H.J. Herz M. Weber W. Heiss P. Senkowitsch-Schmidtke R. Schwaiger M. Stöcklin G. , 1999b. Synthesis and radiopharmacology of O-(2-[¹⁸F]fluoroethyl)-L-tyrosine for tumor imaging. J. Nucl. Med. 40, 205–212.

Booij J. Sokole E.B. Stabin M.G. Janssen A.G.M. de Bruin K. van Royen E.A. , 1998. Human biodistribution and dosimetry of [¹²³I]FP-CIT: a potent radioligand for imaging of dopamine transporters. Eur. J. Nucl. Med. 25, 24–30.

Booij J. Sokole E.B. Stabin M.G. Janssen A.G.M. de Bruin K. van Royen E.A. , 1998. Human biodistribution and dosimetry of [¹²³I]FP-CIT: a potent radioligand for imaging of dopamine transporters: erratum. Eur. J. Nucl. Med. 25, 458.

Boundy K.L. Barnden L.R. Rowe C.C. Reid M. Kassiou M. Katsifis A.G. Lambrecht R.L. , 1995. Human dosimetry and biodistribution of iodine-123-iododexetimide: A SPECT imaging agent for cholinergic muscarinic neuroreceptors. J. Nucl. Med. 36, 1332–1338.

Deterding T.A. Votaw J.R. Wang C.K. Eshima D. Eshima L. Keil R. Malveaux E. Kilts C.D. Goodman M.M. Hoffman J.M. , 2001. Biodistribution and radiation dosimetry of the dopamine transporter ligand [¹⁸F]FECNT. J. Nucl. Med. 42, 376–381.

Gründer G. Siessmeier T. Lange-Asschenfeldt C. Vernaleken I. Buchholz H.-G. Stoeter P. Drzezga A. Lüddens H. Rösch F. Bartenstein P. , 2001. [¹⁸F]Fluoroethylflumaazenil: a novel tracer for PET imaging of human benzodiazepine receptors. Eur. J. Nucl. Med. 28, 1463–1470.

Gründer G. Siessmeier T. Piel M. Vernaleken I. Buchholz H.-G. Zhou Y. Hiemke C. Wong D.P. Rösch F. Bartenstein P. , 2003. Quantification of D₂-like dopamine receptors in the human brain with [¹⁸F]-desmethoxyfallypride. J. Nucl. Med. 44, 109–116.

Kauppinen T.A. Bergström K.A. Heikman P. Hiltunen J. Ahonen A.K. , 2003. Biodistribution and radiation dosimetry of [¹²³I]ADAM in healthy human subjects: preliminary results. Eur. J. Nucl. Med. 30, 132–136.

Kuikka J.T. Bergström K.A. Ahonen A. Länsimies E. , 1994. The dosimetry of iodine-123 labelled 2β-carbomethoxy-3β-(4-iodophenyl)tropane. Eur. J. Nucl. Med. 21, 53–56.

Mitterhauser M. Wadsak W. Wabnegger L. Mien L-K. Tögel S. Langer O. Sieghart W. Viernstein H. Kletter K. Dudczak R. , 2004. Biological evaluation of 2′-[¹⁸F]fluoroflumazenil ([¹⁸F]FFMZ): a potential GABA receptor ligand for PET. Nucl. Med. Biol. 31, 291–295.

Mozley P.D. Stubbs J.T. Kim H-J. McElgin W. Chumpradit S. Kung M-P. Romaniallo G. Kung H.F. , 1995. Dosimetry of a D2/D3 dopamine receptor antagonist that can be used with PET or SPECT. J. Nucl. Med. 36, 1322–1331.

Mozley P.D. Stubbs J.T. Kim H-J. McElgin W. Kung M-P. Meegalla S. Kung H.F. , 1996. Dosimetry of an iodine-123-labeled tropane to image dopamine transporters. J. Nucl. Med. 37, 151–159.

Nosslin B. Johansson L. Leide-Svegborn S. Liniecki J. Mattsson S. Taylor D.M. , 2003. A generic model for [¹¹C]-labelled radiopharmaceuticals for imaging receptors in the human brain. Rad. Prot. Dosim. 105, 587–591.

Taylor D.M. , 2000a. Unpublished assessments.

van de Wiele C. De Vos F. De Sutter J. Dumont F. Slegers G. Dierkx R.A. Thierens H. , 1999. Biokinetics and dosimetry of (iodine-123)-iodomethyl-N,N-dimethyltamoxifen, an (anti)oestrogen receptor radioligand. Eur. J. Nucl. Med. 26, 1259–1264.

Verhoeff N.P. Sokole E.B. Stabin M. Hengst D. Kung H.F. Van Royen E.A. Janssen A.G. , 1993. Dosimetry of iodine-123 iodobenzamide in healthy volunteers. Eur. J. Nucl. Med. 20, 747–752.

Verhoeff N.P. Busemann Sokole E. Hengst D. Stubbs J.B. van Royen E.A. , 1993. Dosimetry of iodine-123 iomazenil in humans. Eur. J. Nucl. Med. 20, 580–584.

Versijpt J. Dumont F. Thierens H. Jansen H. De Vos F. Slegers G. Santens P. Dierckx R.A. Korf J. , 2000. Biodistribution and dosimetry of [¹²³I]iodo-PK 11195: a potential agent for SPET imaging of the peripheral benzodiazepine receptor. Eur. J. Nucl. Med. 27, 1326–1333.

Volkow N.D. Ding Y.S. Fowler J.S. Wang G.J. Logan J. Gatley S.J. Schlyer D.J. Pappas N. , 1995. A new PET ligand for the dopamine transporter: Studies in human brain. J. Nucl. Med. 36, 2162–2168.

Votaw J.R. Ansari M.S. Scott Mason N. Schmidt D. de Paulis T. Holburn G. Clanton J.A. Votlaw D.B. Manning R.G. Kessler R.M. , 1995. Dosimetry of iodine-123-epidepride: A dopamine D2 receptor ligand. J. Nucl. Med. 36, 1316–1321.

Waterhouse R.N. Stabin M.G. Page J.G. , 2003. Preclinical acute toxicity studies and rodent-based dosimetry estimates of the novel sigma-1 receptor radiotracer [¹⁸F]FPS. Nucl. Med. Biol. 30, 555–563.

Deloar H.M. Fujiwara T. Shidahara M. Nakamura T. Watabe H. Narita Y. Itoh M. Miyake M. Watanuki S. , 1998a. Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-D-glucose using whole-body positron emission tomography and magnetic resonance imaging. Eur. J. Nucl. Med. 25, 565–574.

Hays M.T. Segall G.M. , 1999. A mathematical model for the distribution of fluorodeoxyglucose in humans. J. Nucl. Med. 40, 1358–1366.

Hays M.T. Watson E.E. Thomas S.R. Stabin M. , 2002. Radiation absorbed dose estimates from ¹⁸F-FDG. MIRD Dose Estimate Report No. 19. J. Nucl. Med. 43, 210–214.

ICRP, 1987. Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53. Ann. ICRP 18 (1–4).

ICRP, 1998. Radiation dose to patients from radiopharmaceuticals. Addendum 2 to ICRP Publication 53. ICRP Publication 80. Ann. ICRP 28(3).

Meija A.A. Nakamura T. Masatoshi I. Hatazawa J. Mazaki M. Watanuki S. , 1991. Estimation of absorbed doses in humans due to intraveneous administration of fluorine-18-fluorodeoxyglucose in PET studies. J. Nucl. Med. 32, 699–706.

Boyes R.E. Cumming P. Martin W.R.W. McGeer E.G. , 1986. Determination of plasma [¹⁸F]-6-fluorodopa during positron emission tomography; elimination and metabolism in carbidopa treated subjects. Life Sci. 39, 2243–2252.

Brown W.D. Oakes T.R. DeJesus O.T. Taylor M.D. Roberts A.D. Nickles R.J. Holden J.E. , 1998. Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatment. J. Nucl. Med. 39, 1884–1891.

Dhawan V. Belakhlef A. Robeson W. Ishikawa T. Margouleff C. Takikawa S. Chaly T. Kazumata K. Margouleff D. Eidelberg D. , 1996. Bladder wall radiation dose in humans from fluorine-18-FDOPA. J. Nucl Med. 37, 1850–1852.

Harvey J. Firnau G. Garnett E.S. , 1985. Estimation of the radiation dose in man due to 6-[¹⁸F]fluoro-L-dopa. J. Nucl. Med. 26, 931–935.

Heiss W.D. Wienhard K. Wagner R. Lanfermann H. Thiel A. Herhoiz K. Pietrak U. , 1996. F-DOPA as an amino acid tracer to detect brain tumors. J Nucl. Med. 37, 1180–1182.

Hoffman J.M. Melega W.P. Hawk T.C. Grafton S.C. Luxen A. Mahoney D.K. Bardo J.R. Huang S.-C. Mazziotta J.C. Phelps M.E. , 1992. The effects of carbidopa administration of 6-[¹⁸F]fluoro-L-DOPA kinetics in positron emission tomography. J. Nucl. Med. 33, 1472–1477.

Lu E. Meyer E. Kuwabara H. Ma Y. Shiraishi M. Evans A.C. , 1995. Reduction of radiation absorbed dose in F-18-DOPA PET studies by hydration-induced voiding. J. Nucl. Med. 36 (Suppl.), 98P.

Luxen A. Guillaume M. Melega W.P. Pike V.W. Solin O. Wagner R. , 1992. Production of 6[¹⁸F]fluoro-L-DOPA and its metabolism in vivo — a critical review. Nucl. Med. Biol. 19, 149–158.

Melega W.P. Hoffman J.M. Luxen A. Nissenson C.H.K. Phelps M.E. Barrio J.P. , 1990. The effects of carbidopa on the metabolism of 6-[¹⁸F]fluoro-L-dopa in rats, monkeys and humans. Life Sci. 47, 149–157.

Meyer G.-J. Waters S.L. Coenen H.H. Luxen A. Maziere B. Långström B. , 1995. PET radiopharmaceuticals in Europe: Current use and data relevant for the formulation of summaries of product characteristics (SPCs). Eur. J. Nucl. Med. 22, 1420–1432.

Pauwels T. Dethy S. Goldman S. Monclus M. Luxen A. , 1994. Effect of catechol-O-methyl transferase inhibition on peripheral and central metabolism of 6-[¹⁸F]Fluoro-L-DOPA. Eur. J Pharmacol. 257, 53–58.

Bergmann R. Brust P. Kampf G. Coenen H.H. Stöcklin G. , 1995. Evaluation of radioselenium labeled selenomethionine, a potential tracer for brain protein synthesis by PET. Nucl. Med. Biol. 22, 475–481.

Coenen H.H. Kling P. Stöcklin G. , 1989. Cerebral metabolism of 1-[2-¹⁸F]fluorotyrosine, a new PET tracer of protein synthesis. J. Nucl. Med. 30, 1367–1372.

Cottrall M.F. Taylor D.M. McElwain T.J. , 1973. Investigations of ¹⁸F-p-fluorophenylalanine for pancreas scanning. Br. J. Radiol. 46, 277–288.

Deloar H.M. Fujiwara T. Nakamura T. Itoh M. Imai D. Miyake M. Watanuki S. , 1998b. Estimation of internal absorbed dose of 1-[methyl-¹¹C] methionine using whole body positron emission tomography. Eur. J. Nucl. Med. 25, 629–633.

ICRP, 1987. Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53. Ann. ICRP 18 (1–4), 149–150.

ICRP, 2001b. Radiation dose to patients from radiopharmaceuticals. Addendum 4 to ICRP Publication, 53.

Inoue T. Tomiyoshi K. Higuichi T. Ahmed K. Sarwar M. Aoyagi K. Amano S. Alyafei S. Zhang H. Endo K. , 1996. Biodistribution studies on 1–3-[Fluorine-18]fluoro-α-methyl tyrosine: A potential tumor-detecting agent. J. Nucl. Med. 39, 663–667.

Schmidt D. Langen K-J. Herzog H. Wirths J. Holschbach M. Kiwit J.C.W. Ziemons K. Coenen H.H. Müller-Gärtner H-W. , 1997. Whole-body kinetics and dosimetry of l-3-[¹²³I]iodo-α-methyltyrosine. Eur. J. Nucl. Med. 24, 1162–1166.

Shoup T.M. Olson J. Hoffman J.M. Votaw J. Eshima D. Eshima L. Camp M. Stabin M. Votaw D. Goodman M. , 1999. Synthesis and evaluation of [¹⁸F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumours. J. Nucl. Med. 40, 331–338.

Stenhouse M.J. Baxter M.S. , 1977. Bomb ¹⁴C as a biological tracer. Nature (Lond.) 267, 828–832.

Stenström K. Leide-Svegborn S. Erlandsson B. Hellborg R. Mattsson S. Nilsson L-E. Nosslin B. Skog G. Wiebert A. , 1996. Application of accelerator mass spectrometry (AMS) for high-sensitivity measurements of ¹⁴CO₂ in long-term studies of fat metabolism. Appl. Radiat. Isot. 47, 417–422.

Taylor D.M. , 2000b. Generic models for radionuclide dosimetry: 11C, 18F or 75Se-labelled amino acids. Appl. Radiat. Isot. 52, 911–922.

Taylor D.M. Cottrall M.F. , 1973. Evaluation of amino acids labelled with ¹⁸F for pancreas scanning. In: Radiopharmaceuticals and Labelled Compounds, Vol. I. IAEA, Vienna, pp. 441–443.

Wester H.J. Herz M. Senkowitsch-Schmidtke R. Schwaiger M. Stöcklin G. Hamacher K. , 1999a. Preclinical evaluation of 4-[¹⁸F]fluoroprolines: diasteromeric effect on metabolism and uptake in mice. Nucl. Med. Biol. 26, 259–265.

Wester H.J. Herz M. Weber W. Heiss P. Senkowitsch-Schmidtke R. Schwaiger M. Stöcklin G. , 1999b. Synthesis and radiopharmacology of O-(2-[¹⁸F]fluoroethyl)-l-tyrosine for tumor imaging. J. Nucl. Med. 40, 205–212.

Taillefer R. Edell S. Innes G. Lister-James J. , 2000. Acute thromboscintigraphy with (99m)Tc-apcitide: Results of the phase 3 multicenter clinical trial comparing 99mTc-apcitide scintigraphy with contrast venography for imaging acute DVT. Multicenter trial investigators. J. Nucl. Med. 41, 1214–1223.

ICRP, 1987. Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53. Ann. ICRP 18 (1–4).

Liniecki J. , 1998. Private communication. Department of Nuclear Medicine, Medical University of Lodz, Lodz.

Surma M.J. , 1998a. Verification of ^99mTc-Ethylenedicysteine (^99mTc-EC) distribution model in the organism. Nucl. Med. Rev. 1, 29–32.

Surma M.J. , 1998b. ^99mTc-Ethylenedicysteine (^99mTc-EC) renal clearance determination error for the multiple- and single-sample methods. Nucl. Med. Rev. 1, 33–40.

Surma M.J. Wiewiora J. Liniecki J. , 1994. Usefulness of ^99mTc-N,N'-ethylene-1-dicysteine complex for dynamic kidney investigations. Nucl. Med. Comm. 15, 628–635.

Barthel H. Wiener M. Dannenberg C. Bettin S. Sattler B. Knapp W.H. , 1997. Age-specific cerebral perfusion in 4- to 15-year-old children: A high-resolution brain SPET study using ^99mTc-ECD. Eur. J. Nucl. Med. 24, 1245–1252.

Holman B.L. Hellman R.S. Goldsmith S.J. Mena I. Leveille J. Gherardi P.G. Moretti J.L. Bischof-Delaloye A. Hill T.C. Rigo P.M. Van Heertum R.L. Ell P.J. Buell U. De Roo M.C. Morgan R.A. , 1989. Biodistribution, dosimetry and clinical evaluation of technetium-99m ethyl cysteinate dimer in normal subjects and in patients with chronic cerebral infarction. J. Nucl. Med. 30, 1018–1024.

ICRP, 1987. Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53. Ann. ICRP 18 (1–4).

Léveillé J. Demonceau G. Walovitch R.C. , 1992. Intrasubject comparison between technetium-99m-ECD and technetium-99m-HMPAO in healthy human subjects. J. Nucl. Med. 33, 480–484.

Vallabhajosula S. Zimmerman R.E. Picard M. Stritzke P. Mena I. Hellman R.S. Tikofsky R.S. Stabin M.G. Morgan R.A. Goldsmith S.J. , 1989. Technetium-99m ECD: a new brain imaging agent: In vivo kinetics and biodistribution studies in normal human subjects. J. Nucl. Med. 30, 599–604.

Gerson M.C. Lukes J. Deutsch E. Biniakiewicz D. Rohe R.C. Washburn L.C. Fortman C. Walsh R.A. , 1994. Comparison of technetium 99m Q12 and thallium 201 for detection of angiographically documented coronary artery disease in humans. J. Nucl. Cardiol. 1, 499–508.

ICRP, 1979. Limits for intakes of radionuclides by workers. ICRP Publication 30, Part 1. Ann. ICRP 2 (3/4).

ICRP, 1991b. Radiation dose to patients from radiopharmaceuticals. Addendum 1 to ICRP Publication 53, in: Radiological protection in biomedical research. ICRP Publication 62. Ann. ICRP 22 (3).

ICRP, 1998. Radiation dose to patients from radiopharmaceuticals. Addendum 2 to ICRP Publication 53. ICRP Publication 80. Ann. ICRP 28 (3).

Rossetti C. Vanoli G. Paganelli G. Kwiatkowski M. Zito F. Colombo F. Bonino C. Carpinelli A. Casati R. Deutsch K. Marmion M. Woulfe S.R. Lunghi F. Deutsch E. Fazio F. , 1994. Human biodistribution, dosimetry and clinical use of technetium (III)-99m-Q12. J. Nucl. Med. 35, 1571–1580.

Bischof Delaloye A. Delaloye B. , 1995. Radiolabelled monoclonal antibodies in tumour imaging and therapy: Out of fashion?. Eur. J. Nucl. Med. 22, 571–580.

Britton K.E. Granowska M. , 1987. Radioimmunoscintigraphy in tumour identification. Cancer Surv. 6, 247–267.

Fishman A.J. Khaw B.A. Strauss H.N. , 1989. Quo vadis radioimmune imaging. J. Nucl. Med. 20, 1911–1915.

ICRP, 1987. Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53. Ann. ICRP 18 (1–4).

Bronskill M.J. 1983. Radiation dose estimates for interstitial radiocolloid lymphoscintigraphy. Small colloids Semin. Nucl. Med. 13(1), 20–25.

Eshima D. Fauconnier T. Eshima L. 2000. Radiopharmaceuticals for lymphoscintigraphy; including dosimetry and radiation considerations. Semin. Nucl. med. 30 (1), 25–32.

Wilhelm A.J. Mijnhout G.S. Franssen J. 1999. Eur. J. Nucl. Med. 26, S36–S42.

Higley B. Smith F.W. Smith T. Gemmell H.G. Gupta P.D. Gvozdanovic D.V. Graham D. Hinge D. Davidson J. Lahiri A. , 1993. Technetium-99m-1,2-bis[bis(2-ethoxyethyl) phosphino]ethane: Human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J. Nucl. Med. 34, 30–38.

ICRP, 1979. Limits for intakes of radionuclides by workers. ICRP Publication 30, Part 1. Ann. ICRP 2 (3/4).

ICRP, 1987. Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53. Ann. ICRP 18 (1–4).

ICRP, 1991b. Radiation dose to patients from radiopharmaceuticals. Addendum 1 to ICRP Publication 53, in: Radiological protection in biomedical research. ICRP Publication 62. Ann. ICRP 22 (3).

Smith T. Lahiri A. Gemmell H.G. Davidson J. Smith F.W. Pickett R.D. Higley B. , 1992. Dosimetry of ^99mTc-P53 a new myocardial perfusion imaging agent. In: Schlafke-Stelson A. Watson E.E. (Eds.), Fifth International Radiopharmaceutical Dosimetry Symposium. CONF-910529. Oak Ridge Associated Universities, Oak Ridge, TN, pp. 467–481.

Bischof Delaloye A. Delaloye B. , 1995. Radiolabelled monoclonal antibodies in tumour imaging and therapy: Out of fashion?. Eur. J. Nucl. Med. 22, 571–580.

Britton K.E. Granowska M. , 1987. Radioimmunoscintigraphy in tumour identification. Cancer Surv. 6, 247–267.

Fishman A.J. Khaw B.A. Strauss H.N. , 1989. Quo vadis radioimmune imaging. J. Nucl. Med. 20, 1911–1915.

ICRP, 1987. Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53. Ann. ICRP 18 (1–4).

Bajc M. Palmer J. Ohlsson T. Edenbrandt L. , 1994. Distribution and dosimetry of ¹¹¹In DTPA-D-Phe-octreotide in man assessed by whole body scintigraphy. Acta Radiol. 35, 53–57.

Claessens R.A.M.J. Koenders E.B. Boerman O.C. Oyen W.J. Borm G.F. van den Meer J.W. Corstens F.H. , 1995. Dissociation of indium from indium-111-labelled diethylene triamine penta-acetic acid conjugated non-specific polyclonal human immunoglobulin G in inflammatory foci. Eur. J. Nucl. Med. 22, 212–219.

Forssell Aronsson E. Fjälling M. Nilsson O. Tisell L.E. Wängberg B. Ahlman H. , 1995. Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide. J. Nucl. Med. 36, 7–12.

Forssell Aronsson E. Lanhede B. Fjälling M. Wängberg B. Tisell L.E. Ahlman H. Mattsson S. , 1999. Pharmacokinetics and dosimetry of ¹¹¹In-DTPA-D-Phe-1-octreotide in patients with neuroendocrine tumours. In: Schlafke-Stelson A.T. Stabin M.G. Sparks R.B. (Eds.), Proceedings of the Sixth International Radiopharmaceutical Dosimetry Symposium ORISE 99-0164. Oak Ridge Associated Universities, Oak Ridge, TN, pp. 643–655.

ICRP, 1987. Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53. Ann. ICRP 18 (1–4).

Koizumi M. Endo K. Watanabe Y. Saga T. Sakahara H. Konishi H. Yamamuro T. Toyama S. , 1989. Pharmacokinetics of internally labeled monoclonal antibodies as a gold standard: Comparison of biodistribution of 75Se-, 111 In-, and 125I-labeled monoclonal antibodies in osteogenic sarcoma xenografts in nude mice. Cancer Res. 49, 1752–1757.

Krenning E.P. Bakker W.H. Kooij P.P.M. Breeman W.A.P. Oei H.Y. de Jong M. Reubi J.C. Visser T.J. Bruns C. Kwekkeboom D.J. Reijs A.E.M. van Hagen P.M. Koper J.W. Lamberts S.W.J. , 1992. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: Metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J. Nucl. Med. 33, 652–658.

Krenning E.P. Kwekkeboom D.J. Bakker W.H. Breeman W.A. Kooij P.P. Oei H.Y. van Hagen M. Postema P.T. de Jong M. Reubi J.C. Visser T.J. Reijs A.E.M. Hofland L.J. Koper J.W. Lamberts S.W.J. , 1993. Somatostatin receptor scintigraphy with (¹¹¹In-DTPA-D-Phe¹)- and (¹²³I-Tyr³)-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 20, 716–731.

Leide-Svegborn S. Nosslin B. Mattsson S. , 1999. Biokinetics and dosimetry of ¹¹¹In-DTPA-D-Phe-1-octreotide in patients. In: Schlafke-Stelson A.T. Stabin M.G. Sparks R.B. (Eds.), Proceedings of the Sixth International Radiopharmaceutical Dosimetry Symposium. ORISE 99-0164. Oak Ridge Associated Universities, Oak Ridge, TN, pp. 631–642.

Stabin M.G. Kooij P.P. Bakker W.H. , 1997. Radiation dosimetry for indium-111-pentetreotide. J. Nucl. Med. 38, 1919–1922.

Casteels M. Foulon V. Mannaerts G.P. van Veldhoven P. , 2003. Alpha-oxidation of 3-methyl-substituted fatty acids and its thiamine dependence. Eur. J. Biochem. 270, 1619–1627.

Caveliers V. Franken P.R. Florian F.L. Lou H. Knapp F.F. Jr. , 1998. Intra-individual comparison of 3(R)-BMIPP and 3(S)-BMIPP isomers in humans. J. Nucl. Med. 39, 1672–1675.

De Geeter F. Caveliers V. Pansar I. Bossuyt A. Franken P.R. , 1998. Effect of oral glucose loading on the biodistribution of BMIPP in normal volunteers. J. Nucl. Med. 39, 1850–1856.

Dudczak R. Schmoliner R. Angelberger P. Knapp F.F. Goodman M.M. , 1986. Structurally modified fatty acids: Clinical potential as tracers of metabolism. Eur. J. Nucl. Med. 12, S45–S48.

Gunnarsson M. Stenström K. Leide-Svegborn S. Faarinen M. Magnusson C.E. Åberg M. Skog G. Hellborg R. Mattsson S. , 2003. Biokinetics and radiation dosimetry for patients undergoing a glycerol tri[1-¹⁴C]oleate fat malabsorption breath test. Appl. Radiat. Isot. 58, 517–526.

Knapp F.F. Jr. Kropp J. , 1995b. Iodine-123-labelled fatty acids for myocardial single-photon emission tomography: Current status and future perspectives. Eur. J. Nucl. Med. 22, 361–381.

Knapp F.F. Jr. Ambrose K.R. Goodman M.M. , 1986. New radioiodinated methyl-branched fatty acids for cardiac studies. Eur. J. Nucl. Med. 12 (Suppl), S39–S44.

Knapp F.F. Jr. Franken P. Kropp J. , 1995a. Cardiac SPECT with iodine-123-labeled fatty acids: Evaluation of myocardial viability with BMIPP. J. Nucl. Med. 36, 1022–1030.

Machulla H.J. Marsmann M. Dutschka K. , 1980. Biochemical concept and synthesis of a radioiodinated phenyl fatty acid for in vivo metabolic studies of the myocardium. Eur. J. Nucl. Med. 5, 171–173.

Reske S.N. , 1985. 123I-phenylpentadecanoic acid as a tracer of cardiac free fatty acid metabolism. Experimental and clinical results. Eur. Heart J. 6 (Suppl B), 39–47.

Reske S.N. Biersack H.J. Lackner K. Machulla H.J. Knopp R. Hahn N. Winkler C. , 1982. Assessment of regional myocardial uptake and metabolism of omega-(p-123I-phenyl) pentadecanoic acid with serial single-photon emission tomography. Nuklearmedizin 21, 249–253.

Sloof G.W. Visser F.C. van Lingen A. Bax J.J. Eersels J. Teule G.J. Knapp F.F. Jr. , 1997. Evaluation of heart-to-organ ratios of 123I-BMIPP and the dimethyl-substituted 123I-DMIPP fatty acid analogue in humans. Nucl. Med. Commun. 18, 1065–1070.

Tamaki N. Morita K. Kuge Y. Tsukamoto E. , 2000. The role of fatty acids in cardiac imaging. J. Nucl. Med. 41, 1525–1534.

Torizuka K. Yonekura Y. Nishimura T. Tamaki N. Uehara T. Ikekubo K. Hino M. , 1991. The phase 1 study of β-methyl-p-(¹²³I)-iodophenyl-pentadecanoic acid (¹²³I-BMIPP). Kagu Igaku 28, 681–690.

Yoshizumi T. Nozaki S. Fukuchi K. Yamasaki K. Fukuchi T. Maruyama T. Tomiyama Y. Yamashita S. Nishimura T. Matsuzawa Y. , 2000. Pharamacokinetics and metabolism of ¹²³I-BMIPP fatty acid analog in healthy and CD36-deficient subjects. J. Nucl. Med. 41, 1134–1138.

Booij J. Sokole E.B. Stabin M.G. Janssen A.G.M. de Bruin K. van Royen E.A. , 1998. Human biodistribution and dosimetry of [¹²³I]FP-CIT: a potent radioligand for imaging of dopamine transporters, Eur. J. Nucl. Med. 25, 24–30.

Booij J. Sokole E.B. Stabin M.G. Janssen A.G.M. de Bruin K. van Royen E.A. , 1998. Human biodistribution and dosimetry of [¹²³I]FP-CIT: a potent radioligand for imaging of dopamine transporters: Erratum. Eur. J. Nucl. Med. 25, 458.

Boundy K.L. Barnden L.R. Rowe C.C. Reid M. Kassiou M. Katsifis A.G. Lambrecht R.L. , 1995. Human dosimetry and biodistribution of iodine-123-iododexetimide: A SPECT imaging agent for cholinergic muscarinic neuroreceptors. J. Nucl. Med. 36, 1332–1338.

Deterding T.A. Votaw J.R. Wang C.K. Eshima D. Eshima L. Keil R. Malveaux E. Kilts C.D. Goodman M.M. Hoffman J.M. , 2001. Biodistribution and radiation dosimetry of the dopamine transporter ligand [¹⁸F]FECNT. J Nucl Med. 42, 376–381.

Gründer G. Siessmeier T. Lange-Asschenfeldt C. Vernaleken I. Buchholz H.-G. Stoeter P. Drzezga A. Lüddens H. Rösch F. Bartenstein P. , 2001. [¹⁸F]Fluoroethylflumaazenil: a novel tracer for PET imaging of human benzodiazepine receptors. Eur. J. Nucl. Med. 28, 1463–1470.

Gründer G. Siessmeier T. Piel M. Vernaleken I. Buchholz H.-G. Zhou Y. Hiemke C. Wong D.P. Rösch F. Bartenstein P. , 2003. Quantification of D₂-like dopamine receptors in the human brain with [¹⁸F]-desmethoxyfallypride. J. Nucl. Med. 44, 109–116.

Kauppinen T.A. Bergström K.A. Heikman P. Hiltunen J. Ahonen A.K. , 2003. Biodistribution and radiation dosimetry of [¹²³I]ADAM in healthy human subjects: preliminary results. Eur. J. Nucl. Med. 30, 132–136.

Kuikka J.T. Bergström K.A. Ahonen A. Länsimies E. , 1994. The dosimetry of iodine-123 labelled 2b-carbomethoxy-3β-(4-iodophenyl)tropane. Eur. J. Nucl. Med., 21, 53–56.

Mitterhauser M. Wadsak W. Wabnegger L. Mien L-K. Tögel S. Langer O. Sieghart W. Viernstein H. Kletter K. Dudczak R. , 2004. Biological evaluation of 2′-[¹⁸F]fluoroflumazenil ([¹⁸F]FFMZ) a potential GABA receptor ligand for PET. Nucl. Med. Biol. 31, 291–295.

Mozley P.D. Stubbs J.T. Kim H-J. McElgin W. Chumpradit S. Kung M-P. Romaniallo G. Kung H.F. , 1995. Dosimetry of a D2/D3 dopamine receptor antagonist that can be used with PET or SPECT. J. Nucl. Med. 36, 1322–1331.

Mozley P.D. Stubbs J.T. Kim H-J. McElgin W. Kung M-P. Meegalla S. Kung H.F. , 1996. Dosimetry of an iodine-123-labeled tropane to image dopamine transporters. J. Nucl. Med. 37, 151–159.

Nosslin B. Johansson L. Leide-Svegborn S. Liniecki J. Mattsson S. Taylor D.M. , 2003. A generic model for [¹¹C]-labelled radiopharmaceuticals for imaging receptors in the human brain. Rad. Prot. Dosim. 105, 587–591.

Taylor D.M. , 2000a. Unpublished assessments.

van de Wiele C. De Vos F. De Sutter J. Dumont F. Slegers G. Dierkx R.A. Thierens H. , 1999. Biokinetics and dosimetry of (iodine-123)-iodomethyl-N,N-dimethyltamoxifen, an (anti)oestrogen receptor radioligand. Eur. J. Nucl. Med. 26, 1259–1264.

Verhoeff N.P. Sokole E.B. Stabin M. Hengst D. Kung H.F. van Royen E.A. Janssen A.G. , 1993. Dosimetry of iodine-123 iodobenzamide in healthy volunteers. Eur. J. Nucl. Med. 20, 747–752.

Verhoeff N.P. Busemann Sokole E. Hengst D. Stubbs J.B. van Royen E.A. , 1993. Dosimetry of iodine-123 iomazenil in humans. Eur. J. Nucl. Med. 20, 580–584.

Versijpt J. Dumont F. Thierens H. Jansen H. de Vos F. Slegers G. Santens P. Dierckx R.A. Korf J. , 2000. Biodistribution and dosimetry of [¹²³I]iodo-PK 11195: a potential agent for SPET imaging of the peripheral benzodiazepine receptor. Eur. J. Nucl. Med. 27, 1326–1333.

Volkow N.D. Ding Y.-S. Fowler J.S. Wang G.-J. Logan J. Gatley S.J. Schlyer D.J. Pappas N. , 1995. A new PET ligand for the dopamine transporter: Studies in human brain. J. Nucl. Med. 36, 2162–2168.

Votaw J.R. Ansari M.S. Scott Mason N. Schmidt D. de Paulis T. Holburn G. Clanton J.A. Votlaw D.B. Manning R.G. Kessler R.M. , 1995. Dosimetry of iodine-123-epidepride: A dopamine D2 receptor ligand. J. Nucl. Med. 36, 1316–1321.

Waterhouse R.N. Stabin M.G. Page J.G. , 2003. Preclinical acute toxicity studies and rodent-based dosimetry estimates of the novel sigma-1 receptor radiotracer [¹⁸F]FPS. Nucl. Med. Biol. 30, 555–563.

Bischof Delaloye A. Delaloye B. , 1995. Radiolabelled monoclonal antibodies in tumour imaging and therapy: Out of fashion?. Eur. J. Nucl. Med. 22, 571–580.

Britton K.E. Granowska M. , 1987. Radioimmunoscintigraphy in tumour identification. Cancer Surv. 6, 247–267.

Fishman A.J. Khaw B.A. Strauss H.N. , 1989. Quo vadis radioimmune imaging. J. Nucl. Med. 20, 1911–1915.

ICRP, 1987. Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53. Ann. ICRP 18 (1–4).

Bischof Delaloye A. Delaloye B. , 1995. Radiolabelled monoclonal antibodies in tumour imaging and therapy: Out of fashion?. Eur. J. Nucl. Med. 22, 571–580.

Britton K.E. Granowska M. , 1987. Radioimmunoscintigraphy in tumour identification. Cancer Surv. 6, 247–267.

Fishman A.J. Khaw B.A. Strauss H.N. , 1989. Quo vadis radioimmune imaging. J. Nucl. Med. 20, 1911–1915.

ICRP, 1987. Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53. Ann. ICRP 18 (1–4).

Atkins H.L. Budinger T.F. Lebowitz E. Ansari A.N. Greene M.W. Fairchild R.G. Ellis K.J. , 1977. Thallium-201 for medical use. Part 3: Human distribution and physical imaging properties. J. Nucl. Med. 18, 133–140.

Bartlett R.D. Lathrop K.A. Faulhaber P.F. Harper P.V. , 1984. Transfer of thallous ion to and from gastrointestinal sections. J. Nucl. Med. 25, P92.

Chen C.T. Lathrop K.A. Harper P.V. Bartlett R.D. Stark V.J. Fultz K.R. Faulhaber P.F. , 1983. Quantitative measurement of long term in vivo thallium distribution in the human. J. Nucl. Med. 24, P50.

Freeman M.R. Kanwar N. Armstrong P.W. , 1986. The variability of thallium half life at rest as compared to exercise. J. Nucl. Med. 27, 997.

Gupta S.M. Herrera N. Spencer R.P. Hosain F. Crucitti T.W. , 1981. Testicular-scrotal content of ²⁰¹Tl and ⁶⁷Ga after intravenous administration. Int. J. Nucl. Med. Biol. 8, 211–213.

Hosain P. Hosain F. , 1981. Revision of gonadal radiation dose to man from thallium-201. In: Proceedings of the Third International Radiopharmaceutical Dosimetry Symposium, Oak Ridge 1980 (FDA 81-8166). Oak Ridge National Laboratories, Oak Ridge, TN, pp. 333–345.

Krahwinkel W. Herzog H. Feinendegen L.E. , 1988. Pharmacokinetics of thallium-201 in normal individuals after routine myocardial scintigraphy. J. Nucl. Med. 29, 1582–1586.

Nettleton J.S. Lawson R.S. Prescott M.C. Morris I.D. , 2004. Uptake, localization, and dosimetry of ¹¹¹In and ²⁰¹Tl in human testes. J. Nucl. Med. 45, 138–146.

Rao D.V. Shepstone B.J. Wilkins H.B. Howell R.W. , 1995. Kinetics and dosimetry of thallium-201 in human testes. J. Nucl. Med. 36, 607–609.

Samson G. Wackers F.J.Th. Becker A.E. Busemann Sokole E. van der Schoot J.B. , 1978. Distribution of thallium-201 in man. In: Oeff K. Schmidt H.A.E. (Eds.), Nuklearmedizin und biokybernetik, Vol. 1. Medico-informationsdienste, Berlin, pp. 385–389.

Thomas S.R. Stabin M.G. Castronovo F.P. , 2005. Radiation-absorbed dose from ²⁰¹Tl-thallous chloride. J. Nucl. Med. 46, 502–508.